ICER Expands Drug Value Comparison Program
This article was originally published in The Pink Sheet Daily
The non-profit Institute for Clinical and Economic Review plans comparative value and price assessments for up to 20 new drugs over the next two years, supported by grant funding.
You may also be interested in...
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.
Company discusses its strategy for negotiating a change in the recently-proposed Medicare coverage decision for Alzheimer’s drugs during a presentation to analysts.
Proposed Medicare national coverage policy would delay access to Alzheimer’s drugs for too long and the government should instead cover the drugs under specific conditions until research already underway comes in, Global Alzheimer’s Platform Foundation president John Dwyer argues.